Movements in the dome of Moderna. The American pharmaceutical company has appointed Jonathan Van-Tam as its new medical adviser. Van-Tam is Professor of Medical Sciences and Health at the University of Nottingham (United Kingdom), according to reports Financial Times.
The new medical advisor was already working part-time with Moderna as a medical advisor. Van-Tam was a member of the UK vaccine task force, during the pandemic, in that group decisions were made over all in the vaccine supply contracts and the main investments in clinical and manufacturing opportunities.
Jonathan held positions with other pharmaceutical companies in the early 2000s, at companies such as SmithKline Beecham, Roche, and Sanofi-Pasteur. Paul Burton, Moderna’s chief medical officer, explains, “Van-Tam’s significant experience and knowledge as an influenza specialist, including its epidemiology, transmission, vaccination and pandemic preparedness, as well as a world-renowned academic and educator, will be a vital asset.” ”.
Jonathan Van-Tam was a member of the UK Vaccine Task Force during the time of the Covid-19 pandemic.
The American pharmaceutical registered losses of 1,301 million dollars in the first half of the year, compared to profits of 5,854 million dollars in the same period a year ago. The company has attributed the fall in its net result to the slowdown in the marketing of the Covid-19 vaccine.
Moderna’s billing has plummeted in the first six months of the year, with a drop of 79.6%. The biotech company has entered 2,206 million dollars, compared to 10,815 million dollars in the same period a year ago. “Sales in the second quarter were on target given the seasonal nature of Covid-19,” said Stéphane Bancel, CEO of Moderna. In the second quarter alone, Moderna’s sales fell 93%, to $344 million.
Of the $6 billion the company expects to bill from Covid-19 vaccines, $4 billion will come from existing deals, while between $2 billion and $4 billion come from additional sales in the United States, Japan, the European Union (EU) and other countries. Approximately 30% of sales will occur in the third quarter, while the remaining 70% will occur in the fourth quarter.
2023-08-21 08:56:48
#Moderna #appoints #medical #advisor
